Our mission to help you navigate the new normal is fueled by subscribers. To enjoy unlimited access to our journalism, subscribe today.
U.S. health officials agreed pay $1.95 billion for 100 million doses of a vaccine made by Pfizer Inc. and BioNTech SE, the latest step in an effort to fight the coronavirus pandemic.
The companies will receive payment upon the receipt of the doses, following regulatory authorization or approval, according to a statement. The government also can acquire up to an additional 500 million doses.
Nations around the world have begun ordering vaccines that are still being tested as part of their efforts to try to blunt the impact of the pandemic that’s roiled economies and killed more than 600,000 people since the beginning of the year. The U.S. has already ordered experimental shots developed by the University of Oxford and AstraZeneca Plc.
The vaccine would be available to the American people for free, according to the government.
Pfizer shares rose more than 5% in pre-market trading. BioNTech climbed about 7%.
More coronavirus coverage from Fortune:
- We don’t have enough of the air filters capable of stopping the coronavirus
- Flights with empty middle seats decrease COVID risk 79%, study says
- Welcome to the “cat bond” market, where pandemics and hurricanes can mean big returns—or total wipeout
- How chatbots are helping in the fight against COVID-19
- From ball gowns to medical gowns: How one designer changed her business model to help local health care providers
- What the post-pandemic housing market might look like, according to the CEO of Century 21